Geron Corporation
0IV3.L
London Stock Exchange1.46
USD
+0.16
- -
Geron Corporation
0IV3.L
(London Stock Exchange)
Recent
price
1.46
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Geron Corporation (Nasdaq: GERN; LSE: 0IV3) is a commercial-stage biopharmaceutical company focused on developing and commercializing telomerase inhibitors for hematologic malignancies. The company markets RYTELO (imetelstat), a first-in-class telomerase inhibitor approved by the U.S. FDA in June 2024 for the treatment of transfusion-dependent anemia in adults with lower-risk myelodysplastic syndromes who have not responded to or lost response to, or are ineligible for, erythropoiesis-stimulating agents; RYTELO generated $76.5 million in net product revenue in 2024 following its U.S. commercialization launch. Geron's clinical pipeline centers on imetelstat in ongoing trials, including the Phase 3 IMpactMF study in JAK-inhibitor relapsed/refractory myelofibrosis, with enrollment completed in 2025, and exploratory studies in other myeloid hematologic malignancies such as acute myeloid leukemia. In November 2024, Geron secured up to $375 million in non-dilutive financing, comprising a $125 million synthetic royalty agreement with Royalty Pharma on U.S. RYTELO sales and $250 million in senior secured debt from funds managed by Pharmakon Advisors, with $250 million received at closing to support U.S. and potential European launches, the IMpactMF trial, and general operations. The European Commission granted marketing authorization for RYTELO in lower-risk myelodysplastic syndromes in Q1 2025, paving the way for a commercial launch in select EU countries in 2026. These developments mark Geron's transition from a research-focused entity to a revenue-generating commercial biopharma, bolstered by FDA orphan drug exclusivity for RYTELO until June 2031. Founded in 1990 and headquartered in Foster City, California, Geron operates primarily in the United States with plans for European expansion; the company employs 229 people and targets patients with blood cancers through its specialized telomerase inhibition platform, which aims to reduce malignant cell proliferation in the bone marrow.